Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 29 September 2015 | By Zachary Brennan
The International Conference on Harmonization (ICH) has amended its good clinical practice (GCP) guideline with the aim of helping industry address the increasing scale, complexity and cost of clinical trials.
The evolving use of technology and new risk management processes offer opportunities to increase efficiency, ICH says. The updated guideline is intended to provide a unified standard for the regulatory authorities in the EU, Japan, US, Canada and Switzerland to facilitate the mutual acceptance of clinical data.
"This guideline has been amended to encourage implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting while continuing to ensure human subject protection and data integrity," the amended guideline says. "Standards regarding electronic records and essential documents intended to increase clinical trial quality and efficiency have also been updated."
The longest addendum to the guideline is centered on a sponsor's quality management, which includes the efficient design of trial protocols, data collection tools and procedures, and the collection of data essential to decision making.
The broad ICH recommendations call on sponsors to identify processes and data "that are critical to assure human subject protection and the reliability of study results." And as for risks, ICH says they should be considered at both the system level (e.g., facilities, standard operating procedures, computerized systems, personnel, vendors) and clinical trial level (e.g., investigational product, trial design, data collection and recording).
Risks should be evaluated by considering: (a) the likelihood of errors occurring, given existing risk controls; (b) the impact of such errors on human subject protection and data integrity; and (c) the extent to which such errors would be detectable.
In addition to quality management, sponsors should develop a systematic, prioritized, risk-based approach to monitoring clinical trials, ICH says. The group advocates for a flexible approach intended to improve the effectiveness and efficiency of monitoring.
"A combination of on-site and centralized monitoring activities may be appropriate," though sponsors "should document the rationale for the chosen monitoring strategy," ICH says.
As far as why centralized monitoring processes are important, ICH says they can complement and reduce the extent and/or frequency of on-site monitoring by such methods as: Routine review of submitted data; identification of missing data, inconsistent data, data outliers or unexpected lack of variability and protocol deviations that may be indicative of systematic or significant errors in data collection and reporting at a site or across sites; using statistical analyses to identify data trends such as the range and consistency of data within and across sites; and analyzing site characteristics and performance metrics.
ICH also updated the guideline, among other topics, on the responsibilities for supervising any delegated or outsourced study tasks conducted at a trial site, as well as how to maintain adequate and accurate source documents and trial records.
ICH GCP Guideline
Tags: ICH, clinical trials guidelines, GCP guideline, clinical trial quality
Regulatory Focus newsletters
All the biggest regulatory news and happenings.